Clinical trials: Herpes Zoster
- Condition Herpes Zoster
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
- Trial name
- NCT06447779
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- 4 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Shingles, Herpes Zoster
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT06569823
- Testing
- Z-1018, Shingrix
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Herpes Zoster
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to…
- Trial name
- NCT05636436
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
- Trial name
- NCT05856084
- Testing
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control
- Where
- China
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
- Trial name
- NCT06654700
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete…
- Trial name
- NCT07293065
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- 4 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
- Trial name
- NCT05701800
- Testing
- mRNA-1468, Shingrix
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 659 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Shingles, Herpes Zoster Infection
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV…
- Conditions
- Shingles, Herpes Zoster Infection, Human
- Trial name
- NCT05703607
- Testing
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Where
- 35 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes Zoster (HZ), Infectious Diseases
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Trial name
- NCT06581575
- Testing
- JCXH-105, Shingrix
- Where
- 8 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Herpes Zoster
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of…
- Trial name
- NCT06375512
- Testing
- HZ Vaccine (IN001), Shingrix
- Where
- 3 sites in United States, Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal…
- Trial name
- NCT07481604
- Testing
- Shingrix, CVI-VZV-001
- Where
- 7 sites in South Korea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Herpes Zoster, mRNA Vaccine
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations…
- Trial name
- NCT07400003
- Testing
- Low-dose experimental vaccine, High-dose experimental vaccine, Active-controlled vaccine A
- Where
- China
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Herpes Zoster
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07354659
- Testing
- A zoster mRNA vaccine SYS6017, Active Comparator Vaccine
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Herpes Zoster (HZ), Shingles
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
- Conditions
- Herpes Zoster (HZ), Shingles, VZV, Recombinant Zoster Vaccine
- Trial name
- NCT07311148
- Testing
- Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Herpes Zoster, Herpes Zoster Vaccine
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine…
- Trial name
- NCT02723773
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 161 sites in United States, Australia and 16 more
- Volunteers
- 7,539 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50…
- Trial name
- NCT07205796
- Testing
- HZ Vaccine (IN001), Shingrix
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd